Heimberg R G, Liebowitz M R
Social Phobia Program, University at Albany, State University of New York 12205, USA.
Int Clin Psychopharmacol. 1996 Jun;11 Suppl 3:55-64. doi: 10.1097/00004850-199606003-00010.
Scientific evaluation of the efficacy of treatments for mental disorders is an undertaking of critical importance. However, the design of trials evaluating psychosocial treatments may determine whether or not they will ultimately provide meaningful data that may guide further treatment development. In this paper, we address areas of methodological concern in the evaluation of psychosocial treatments. These are discussed in the context of psychosocial treatments for social phobia, whether they be the sole focus of an outcome trial, compared to other psychosocial or pharmacological treatments, or combined with pharmacotherapies. We address issues of patient representativeness, adequacy of treatment as conducted, selection and design of control conditions, and assessment of change over the course of treatment for social phobia. Most of these issues have implications for the evaluation of pharmacotherapies for social phobia as well.
对精神障碍治疗效果进行科学评估是一项至关重要的工作。然而，评估心理社会治疗的试验设计可能决定这些治疗最终能否提供有意义的数据，从而指导进一步的治疗发展。在本文中，我们探讨心理社会治疗评估中方法学方面值得关注的领域。这些领域将在社交恐惧症心理社会治疗的背景下进行讨论，无论它们是一项疗效试验的唯一重点、与其他心理社会或药物治疗进行比较，还是与药物疗法联合使用。我们将探讨患者代表性问题、实际实施治疗的充分性、对照条件的选择和设计，以及社交恐惧症治疗过程中的变化评估。其中大多数问题对社交恐惧症药物治疗的评估也有影响。
